Vertex Pharmaceuticals Incorporated: Genetic Diseases, Inborn trials
The registry lists 11 Genetic Diseases, Inborn studies with Vertex Pharmaceuticals Incorporated as lead sponsor. 3 are open to participants now and 5 have results posted.
Phase 1 1Phase 2 6Phase 3 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type IEnrolling by invitationNCT06926621Phase 2
- Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseaseRecruitingNCT05477563Phase 3
- A Long-term Follow-up Study in Participants Who Received CTX001Enrolling by invitationNCT04208529Phase 3
- Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR MutationTerminatedNCT00953706Phase 2Results posted
- Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D MutationCompletedNCT00909727Phase 3Results posted
- Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D MutationCompletedNCT00909532Phase 3Results posted
- Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene MutationCompletedNCT00865904Phase 2Results posted
- Safety Study of Ivacaftor in Subjects With Cystic FibrosisCompletedNCT00457821Phase 2Results posted
- A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)Active, not recruitingNCT06185764Phase 1/2
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)Active, not recruitingNCT05356195Phase 3
- A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-ThalassemiaCompletedNCT03655678Phase 2/3